MetaADEDB 2.0 @ LMMD
histrelin
(HHXHVIJIIXKSOE-QILQGKCVSA-N)
Structure
SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1ncn(c1)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCN=C(N)N
Molecular Formula:
C66H86N18O12
Molecular Weight:
1323.500
Log P:
3.7978
Hydrogen Bond Acceptor:
28
Hydrogen Bond Donor:
15
TPSA:
449.36
CAS Number(s):
76712-82-8
Synonym(s)
1.
histrelin
2.
((im bzl)-D-His(6), Pro(9)-NEt)LHRH
3.
6-His(imBzl)-9-N-Et-ProNH2-10-des-GlyNH2-LHRH
4.
GnRH, His(imBzl)(6)-N-Et-ProNH2(9)-
5.
IBHPE-LHRH
6.
LHRH, His(imBzl)(6)-N-Et-ProNH2(9)-
7.
LHRH, histidyl(imBzl)(6)-N-ethylprolinamide(9)-des-glycinamide(10)-
8.
Supprelin
9.
imbzl-His(6), Pro(9)-NET-GNRH
External Link(s)
MeSHC029256
PubChem Compound25077993
ChEBI5739
CHEMBLCHEMBL1201255
DrugCentral2975
IUPHAR/BPS Guide to PHARMACOLOGY3884
KEGGdr:D02369
Therapeutic Target DatabaseD0O7DG
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 108US FAERS
2Device breakageFAERS: 96SIDER
US FAERS
3Procedural complicationFAERS: 67US FAERS
4Incorrect drug administration durationFAERS: 64US FAERS
5Implant site rashFAERS: 38US FAERS
6Device expulsionFAERS: 20US FAERS
7Implant site infectionFAERS: 20US FAERS
8Implant site painFAERS: 18US FAERS
9Mood swingsFAERS: 17SIDER
US FAERS
10Delayed PubertyFAERS: 13US FAERS
11HeadacheFAERS: 13SIDER
US FAERS
12Implant site erythemaFAERS: 12US FAERS
13UrticariaFAERS: 12US FAERS
14HypersensitivityFAERS: 11US FAERS
15No adverse eventFAERS: 9US FAERS
16PruritusFAERS: 9SIDER
US FAERS
17ErythemaFAERS: 8SIDER
US FAERS
18Incorrect product administration durationFAERS: 8US FAERS
19Peripheral swellingFAERS: 8US FAERS
20Rash erythematousFAERS: 8US FAERS
21Device dislocationFAERS: 7US FAERS
22Implant site pruritusFAERS: 7US FAERS
23Implant site swellingFAERS: 7US FAERS
24Product quality issueFAERS: 7US FAERS
25ArthralgiaFAERS: 6SIDER
US FAERS
26Complication of device removalFAERS: 6US FAERS
27Device extrusionFAERS: 6US FAERS
28DizzinessFAERS: 6SIDER
US FAERS
29Emotional disorderFAERS: 6US FAERS
30Implant site dischargeFAERS: 6US FAERS
31Implant site irritationFAERS: 6US FAERS
32VomitingFAERS: 6SIDER
US FAERS
33Abdominal PainFAERS: 5US FAERS
34AcneFAERS: 5US FAERS
35Implant site bruisingFAERS: 5US FAERS
36Implant site scarFAERS: 5US FAERS
37Implant site urticariaFAERS: 5US FAERS
38Inappropriate schedule of drug administrationFAERS: 5US FAERS
39PubertyFAERS: 5US FAERS
40Vaginal DischargeFAERS: 5US FAERS
41Blood testosterone increasedFAERS: 4SIDER
US FAERS
42Delayed menarcheFAERS: 4US FAERS
43Device malfunctionFAERS: 4US FAERS
44Incision site rashFAERS: 4US FAERS
45MalaiseFAERS: 4SIDER
US FAERS
46PneumoniaFAERS: 4US FAERS
47Adverse eventFAERS: 3US FAERS
48AlopeciaFAERS: 3US FAERS
49AnxietyFAERS: 3US FAERS
50AstheniaFAERS: 3SIDER
US FAERS
51Back PainFAERS: 3SIDER
US FAERS
52CryingFAERS: 3US FAERS
53Disease ProgressionFAERS: 3SIDER
US FAERS
54EczemaFAERS: 3US FAERS
55Feeling abnormalFAERS: 3SIDER
US FAERS
56Hormone level abnormalFAERS: 3US FAERS
57Implant site cellulitisFAERS: 3US FAERS
58Implant site reactionFAERS: 3SIDER
US FAERS
59Incision site painFAERS: 3US FAERS
60Migration of implanted drugFAERS: 3US FAERS
61Night sweatsFAERS: 3SIDER
US FAERS
62Post procedural complicationFAERS: 3US FAERS
63SwellingFAERS: 3SIDER
US FAERS
64Therapeutic response unexpectedFAERS: 3US FAERS
65Unevaluable eventFAERS: 3US FAERS
66AbscessFAERS: 2US FAERS
67Activities of daily living impairedFAERS: 2US FAERS
68Alanine Aminotransferase IncreasedFAERS: 2US FAERS
69AngerFAERS: 2US FAERS
70Application site pruritusFAERS: 2US FAERS
71Aspartate Aminotransferase IncreasedFAERS: 2SIDER
US FAERS
72Astrocytoma, low gradeFAERS: 2US FAERS
73Blood alkaline phosphatase increasedFAERS: 2US FAERS
74Blood follicle stimulating hormone increasedFAERS: 2US FAERS
75Blood gonadotrophin increasedFAERS: 2US FAERS
76Blood lactate dehydrogenase increasedFAERS: 2SIDER
US FAERS
77Drug dose omissionFAERS: 2US FAERS
78Early menarcheFAERS: 2US FAERS
79Emotional distressFAERS: 2US FAERS
80EnuresisFAERS: 2US FAERS
81FatigueFAERS: 2SIDER
US FAERS
82HypersomniaFAERS: 2US FAERS
83Implant site abscessFAERS: 2US FAERS
84Implant site dermatitisFAERS: 2US FAERS
85Implant site necrosisFAERS: 2US FAERS
86Implant site vesiclesFAERS: 2US FAERS
87Incision site complicationFAERS: 2US FAERS
88Incision site erythemaFAERS: 2US FAERS
89Incision site swellingFAERS: 2US FAERS
90InfectionFAERS: 2SIDER
US FAERS
91Joint injuryFAERS: 2US FAERS
92Lip swellingFAERS: 2US FAERS
93Malignant neoplasm progressionFAERS: 2US FAERS
94Memory impairmentFAERS: 2US FAERS
95MenarcheFAERS: 2US FAERS
96MetrorrhagiaFAERS: 2SIDER
US FAERS
97NasopharyngitisFAERS: 2US FAERS
98Nerve injuryFAERS: 2US FAERS
99ParanoiaFAERS: 2US FAERS
100Personality ChangeFAERS: 2US FAERS
101PolymyositisFAERS: 2US FAERS
102Product use issueFAERS: 2US FAERS
103Skin irritationFAERS: 2US FAERS
104SyncopeFAERS: 2US FAERS
105Wrong technique in drug usage processFAERS: 2US FAERS
106Accidental underdoseFAERS: 1US FAERS
107Administration site discomfortFAERS: 1US FAERS
108Administration site reactionFAERS: 1US FAERS
109Administration site scabFAERS: 1US FAERS
110ApathyFAERS: 1US FAERS
111Application site erythemaFAERS: 1US FAERS
112Application site painFAERS: 1SIDER
US FAERS
113Application site rashFAERS: 1US FAERS
114Application site swellingFAERS: 1US FAERS
115ArthritisFAERS: 1US FAERS
116AstrocytomaFAERS: 1US FAERS
117Bilateral breast budsFAERS: 1US FAERS
118BlindnessFAERS: 1US FAERS
119Blood creatine phosphokinase increasedFAERS: 1US FAERS
120Blood follicle stimulating hormone abnormalFAERS: 1US FAERS
121Blood pressure fluctuationFAERS: 1US FAERS
122Blood testosterone abnormalFAERS: 1US FAERS
123Blood triglycerides increasedFAERS: 1US FAERS
124Bone density decreasedFAERS: 1SIDER
US FAERS
125Bone painFAERS: 1SIDER
US FAERS
126BradycardiaFAERS: 1US FAERS
127Brain DeathFAERS: 1US FAERS
128Breast CystFAERS: 1US FAERS
129Breast tendernessFAERS: 1SIDER
US FAERS
130Bronchial secretion retentionFAERS: 1US FAERS
131Cardiovascular insufficiencyFAERS: 1US FAERS
132Carotid artery occlusionFAERS: 1US FAERS
133CellulitisFAERS: 1US FAERS
134Cerebrovascular accidentFAERS: 1US FAERS
135Complication of device insertionFAERS: 1US FAERS
136CystFAERS: 1US FAERS
137Deafness NeurosensoryFAERS: 1US FAERS
138DeformityFAERS: 1US FAERS
139Depressed moodFAERS: 1US FAERS
140DermatitisFAERS: 1US FAERS
141Device defectiveFAERS: 1US FAERS
142Device difficult to useFAERS: 1US FAERS
143Device kinkFAERS: 1US FAERS
144Device leakageFAERS: 1US FAERS
145Device material issueFAERS: 1US FAERS
146Device migrationFAERS: 1US FAERS
147Disease recurrenceFAERS: 1US FAERS
148Drug administered at inappropriate siteFAERS: 1US FAERS
149Drug administration errorFAERS: 1US FAERS
150Drug effect delayedFAERS: 1US FAERS
151Dry skinFAERS: 1US FAERS
152DysphemiaFAERS: 1US FAERS
153Encapsulation reactionFAERS: 1US FAERS
154Expired product administeredFAERS: 1US FAERS
155Expulsion of medicationFAERS: 1US FAERS
156Failure of implantFAERS: 1US FAERS
157FluctuanceFAERS: 1US FAERS
158FlushingFAERS: 1SIDER
US FAERS
159Grip strength decreasedFAERS: 1US FAERS
160Growth retardationFAERS: 1US FAERS
161Human chorionic gonadotropin increasedFAERS: 1US FAERS
162HydrocephalusFAERS: 1US FAERS
163HypertrichosisFAERS: 1US FAERS
164Iatrogenic injuryFAERS: 1US FAERS
165Impaired work abilityFAERS: 1US FAERS
166Implant site erosionFAERS: 1US FAERS
167Implant site indurationFAERS: 1US FAERS
168Implant site inflammationFAERS: 1US FAERS
169Implant site noduleFAERS: 1US FAERS
170Implant site pustulesFAERS: 1US FAERS
171Incision site pruritusFAERS: 1US FAERS
172InflammationFAERS: 1SIDER
US FAERS
173Injection site scabFAERS: 1US FAERS
174Intentional medical device removal by patientFAERS: 1US FAERS
175Intestinal PerforationFAERS: 1US FAERS
176Joint stiffnessFAERS: 1US FAERS
177Joint swellingFAERS: 1US FAERS
178LethargyFAERS: 1SIDER
US FAERS
179LeukodystrophyFAERS: 1US FAERS
180Limb injuryFAERS: 1US FAERS
181LipoatrophyFAERS: 1US FAERS
182Medical device removalFAERS: 1US FAERS
183Metastases to stomachFAERS: 1US FAERS
184MiliariaFAERS: 1US FAERS
185Musculoskeletal stiffnessFAERS: 1US FAERS
186NauseaFAERS: 1SIDER
US FAERS
187Neck PainFAERS: 1SIDER
US FAERS
188NervousnessFAERS: 1US FAERS
189NeurofibrosarcomaFAERS: 1US FAERS
190Ocular vascular disorderFAERS: 1US FAERS
191Oropharyngeal painFAERS: 1US FAERS
192Osteogenesis ImperfectaFAERS: 1US FAERS
193PainFAERS: 1SIDER
US FAERS
194PalpitationsFAERS: 1SIDER
US FAERS
195Patient-device incompatibilityFAERS: 1US FAERS
196Pharmaceutical product complaintFAERS: 1US FAERS
197Pituitary cystFAERS: 1US FAERS
198Postoperative adhesionFAERS: 1US FAERS
199Precocious PubertyFAERS: 1US FAERS
200Premenstrual syndromeFAERS: 1US FAERS
201Product lot number issueFAERS: 1US FAERS
202Product size issueFAERS: 1US FAERS
203PsoriasisFAERS: 1US FAERS
204Retinal migraineFAERS: 1US FAERS
205SeromaFAERS: 1US FAERS
206ShockFAERS: 1SIDER
US FAERS
207Shunt occlusionFAERS: 1US FAERS
208StaringFAERS: 1US FAERS
209StrabismusFAERS: 1US FAERS
210Suicide attemptFAERS: 1US FAERS
211Temperature regulation disorderFAERS: 1US FAERS
212Testicular hypertrophyFAERS: 1US FAERS
213Therapy cessationFAERS: 1US FAERS
214Therapy changeFAERS: 1US FAERS
215ThirstFAERS: 1US FAERS
216Throat irritationFAERS: 1US FAERS
217TremorFAERS: 1SIDER
US FAERS
218Vascular occlusionFAERS: 1US FAERS
219VertigoFAERS: 1US FAERS
220Viral upper respiratory tract infectionFAERS: 1US FAERS
221Visual ImpairmentFAERS: 1US FAERS
222Weight decreasedFAERS: 1SIDER
US FAERS
223Wound infection staphylococcalFAERS: 1US FAERS
224Abdominal discomfortSIDER
225AmblyopiaSIDER
226Back pain aggravatedSIDER
227Blood and lymphatic system disordersSIDER
228Blood glucose increasedSIDER
229ConstipationSIDER
230Creatinine renal clearance decreasedSIDER
231Device occlusionSIDER
232DiscomfortSIDER
233Disturbance in sexual arousalSIDER
234DysuriaSIDER
235EpistaxisSIDER
236Erectile dysfunctionSIDER
237Gynecomastia aggravatedSIDER
238Hematuria aggravatedSIDER
239HypotrichosisSIDER
240Implant breakageSIDER
241Instillation site painSIDER
242Local reactionSIDER
243MalnutritionSIDER
244MenorrhagiaSIDER
245Musculoskeletal discomfortSIDER
246MyalgiaSIDER
247NephrolithiasisSIDER
248Pain worsenedSIDER
249Paresthesia lower limbSIDER
250Pituitary AdenomaSIDER
251Pituitary ApoplexySIDER
252Pituitary infarctionSIDER
253Post procedural painSIDER
254Prostatic acid phosphatase increasedSIDER
255Renal failure aggravatedSIDER
256Serum testosterone increasedSIDER
257Sexual DysfunctionSIDER
258Stargardt's diseaseSIDER
259Stent occlusionSIDER
260Suture related complicationSIDER
261Traumatic liver injurySIDER
262Urinary RetentionSIDER
263Urinary frequency aggravatedSIDER
264Wound InfectionSIDER
265nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120269

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.